The Quantellect read.As of Nov 19, 2026, 7 active firms cover Quince Therapeutics, Inc: 6 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $4.00 to $82.00 (about 20.5x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $54.29 sits 41% above the current $38.45. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.11 next quarter toward $-4.68 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy686%
Neutral114%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$54.29
+41.2% upside
Average target across 7 active firms as of Nov 19, 2026 vs $38.45 current
Highest Target$82.00
Average Target$54.29
Lowest Target$4.00
Detailed analyst forecasts for QNCX
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 6 of 7 active firms rate QNCX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
QNCX EPS & revenue forecast
EPS · NEXT QUARTER
$-1.11
Range $-1.60 – $-0.71 · 3 analysts · -99% YoY
Next period, 3 analysts expect Quince Therapeutics, Inc. to earn $-1.11 a share (range $-1.60 – $-0.71), versus $-152.00 a year earlier. Full-year consensus is $-3.65, growing to $-4.68 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Quince Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on QNCX.
#1
Jonathan Wolleben
JMP Securities · Rank #54
Buy
$77.00+100.3% to target
Overall win rate
43%
+ Follow
#2
Joseph Schwartz
Leerink Partners · Rank #242
Buy
$80.00+108.1% to target
Overall win rate
36%
+ Follow
#3
Leland Gershell
Oppenheimer · Rank #404
Buy
$2000.00+5101.6% to target
Overall win rate
35%
+ Follow
#4
Jason Kolbert
D. Boral Capital · Rank #562
Neutral
No targeton QNCX
Overall win rate
22%
+ Follow
#5
Jason McCarthy
Maxim Group · Rank #567
Neutral
No targeton QNCX
Overall win rate
30%
+ Follow
QNCX stock forecast FAQ
What is QNCX's average 12-month price target?+
The 7 active firms with a live target average $54.29 for Quince Therapeutics, Inc. over the next 12 months, ranging from a $82.00 high to a $4.00 low, as of Nov 19, 2026.
Is QNCX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for QNCX?+
The Street-high target is $82.00 (Oppenheimer), and the Street-low is $4.00 (Leerink Partners). The average of all 7 active-firm targets is $54.29.
How many active Wall Street firms cover QNCX?+
7 active firms have a recognized rating on Quince Therapeutics, Inc. as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering QNCX?+
Among analysts who currently cover QNCX, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #54). Their current call is Buy with a $77.00 target.
What is Quince Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-1.11 per share (range $-1.60 – $-0.71) across 3 analysts. Full-year EPS is projected at $-3.65, rising to $-4.68 the following year.
How much revenue is Quince Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading QNCX lately?+
As of Nov 19, 2026, 6 of 7 active firms rate QNCX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their QNCX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.